Calebin A
Based on 1 Customer Validation
Calebin A is a PI3K/Akt/mTOR, MAPK, and NF-κB inhibitor with oral effectiveness. Calebin A can block the autophagy-repressive, inhibiting apoptosis. Calebin A has anti-tumor activity by epigenetic regulation. Calebin A suppresses adipogenesis, modulates thermogenesis, and enriches gut probiotics. Calebin A can be used in research on osteoarthritis, Alzheimer's disease, type 2 diabetes, malignant peripheral nerve sheath tumors, and colorectal cancer.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 336784-82-8
- Formula: C21H20O7
- Molecular Weight:384.38
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| IMR-32 | ED50 |
1.4 μg/mL
Compound: 1
|
Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards IMR-32 human neuroblastoma cell
Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards IMR-32 human neuroblastoma cell
|
[PMID: 11549465] |
| PC-12 | ED50 |
1 μg/mL
Compound: 1
|
Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards PC12 rat pheochromocytoma cell
Evaluated for neuronal cell protectivity against beta-amyloid (25,35) insult towards PC12 rat pheochromocytoma cell
|
[PMID: 11549465] |
| PC-12 | ED50 |
1 μg/mL
Compound: 1, calebin-A
|
Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay
Protection against beta-amyloid (25 to 35) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay
|
[PMID: 12350137] |
| PC-12 | ED50 |
2 μg/mL
Compound: 1, calebin-A
|
Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay
Protection against beta-amyloid (1 to 42) insult in rat PC12 cells assessed as viable cells after 24 hrs by MTT assay
|
[PMID: 12350137] |
In Vitro
Calebin A (5 μM) suppresses apoptosis and promotes autophagic Beclin-1 expression in primary canine chondrocytes cultured in an osteoarthritis environment[1].
Calebin A (5 μM) upregulates ECM and autophagy markers, downregulates inflammation, degradation, apoptosis, and mTOR/PI3K/Akt signaling in primary canine chondrocytes cultured in an osteoarthritis environment, with effects dependent on intact autophagy[1].
Calebin A inhibits colonosphere formation, proliferation, invasion/migration, and enhances apoptosis in HCT116, RKO, and SW480 colorectal cancer cells via modulation of TNF-β/NF-κB signaling and associated biomarkers[2].
Calebin A overcomes vincristine resistance, induces G2/M-phase arrest and apoptosis in SGC7901 gastric cancer cells via modulation of MAPK signaling and P-glycoprotein[2].
Calebin A reduces growth and viability of Sup-T1 lymphoma cells and modulates epigenetic enzymes (HAT, HDAC, PCAF)[2].
Calebin A down-regulates inflammation in canine tenocytes via NF-κB/Scleraxis signaling[2].
Calebin A (20 μM) suppresses adipogenesis and induces lipolysis in adipocytes, with lipolysis induced at 20 μM[2].
Calebin A (25 μM; 24 h) induces G2/M phase decrease and G1 phase increase in STS26T, S462-TY, ST8814, and T265 MPNST cells, arresting cell cycle progression[3].
Calebin A (12.5-25 μM) downregulates phosphorylated AKT, phosphorylated ERK1/2, survivin, hTERT, and acetylated histone H3 in MPNST cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:S462-TY, ST8814, T265, STS26T MPNST cell lines; LinNF primary neurofibroma cells
-
Concentration:6.25, 12.5, 25, 50, 100 μM
-
Incubation Time:24 h
-
Result:Decreased viability of MPNST cell lines at 12.5-25 μM; reduced survival by less than 50% in all MPNST cell lines with 25 μM treatment; inhibited growth of primary neurofibroma cells.
-
Cell Line:STS26T, S462-TY, ST8814, T265 MPNST cell lines
-
Concentration:25 μM
-
Incubation Time:24 h
-
Result:Decreased STS26T cells in G2/M phase from 12.6% to 11.4% and increased G1 phase from 73.6% to 74.6%; reduced S462-TY G2/M phase from 19.7% to 8.8%, ST8814 G2/M phase from 6.4% to 6.0%, and T265 G2/M phase from 23.1% to 18.3%.
-
Cell Line:HCT116 colorectal cancer cells (co-cultured with MRC-5 fibroblasts and Jurkat T-lymphocytes in multicellular proinflammatory TME; or co-cultured with MRC-5 fibroblasts and 10 ng/ml TNF-β in TNF-β-TME)
-
Concentration:1-5 μM (10 days treatments); 5 μM (4 h immunofluorescence assay)
-
Incubation Time:10 days (MTT, colonosphere, invasion, Western blotting); 4 h (immunofluorescence)
-
Result:Dose-dependently inhibited HCT116 cell proliferation, with maximum inhibition at 5 μM. Reduced colonosphere formation and invasion dose-dependently. Decreased nuclear p65-NF-κB labeling to 21% in multicellular TME and 22% in TNF-β-TME at 5 μM after 4 h treatment. Increased apoptosis to 59% in multicellular TME and 48% in TNF-β-TME at 5 μM after 4 h treatment. Suppressed p65-NF-κB phosphorylation, NF-κB-regulated gene products (MMP-9, CXCR4, Ki-67, β1-integrin), and cancer stem cell markers (CD133, CD44, ALDH1) dose-dependently. Increased cleaved caspase-3 dose-dependently.
Parmacokinetics
In Vivo
Calebin A (500 mg/kg; oral; single dose ) exhibits pharmacokinetic properties including ~0.5% bioavailability, 1-3 hour serum half-life, and primarily non-renal excretion in male Sprague-Dawley rats[2].
Calebin A (100 mg/kg; i.p.; three times a week; 15 days) significantly reduces xenograft tumor size in a mouse MPNST model[3].
Calebin A (0.1-0.5%; dietary supplementation; daily; 12 weeks) exhibits dose-dependent anti-obesity effects in high-fat diet-induced obese mice by reducing body weight and blood glucose, restoring liver weight, enhancing adaptive thermogenesis, and modulating gut microbiota composition[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (male, 4 weeks old, MPNST xenograft model with S462-TY cells)[3]
-
Dosage:100 mg/kg
-
Administration:i.p.; three times a week; 15 days
-
Result:Significantly decreased xenograft tumor size two weeks post-treatment.
-
Animal Model:C57BL/6 (male, 4 weeks old, high-fat diet-induced obesity)[4]
-
Dosage:0.1%; 0.5%
-
Administration:high-fat diet (HFD) supplementation; daily; 12 weeks
-
Result:Reduced body weight in a dose-dependent manner; lowered fasting blood glucose and liver weight to normal diet levels (0.5% dose); decreased weights of white, beige, and brown adipose tissues (0.5% dose); improved liver color by reducing lipid accumulation (0.5% dose); better maintained rectal temperature with a higher area under the curve for temperature change than the high-fat diet group during 4°C cold exposure (0.5% dose); reduced Firmicutes-to-Bacteroidetes ratio from 1.24 ± 0.29 to 1.03 ± 0.42 (0.5% dose); increased Verrucomicrobia phylum abundance from 0.002 ± 0.001 to 0.022 ± 0.02 (0.5% dose); enriched genera including Akkermansia, Butyricicoccus, Ruminiclostridium_9, and unidentified_Ruminococcaceae (0.5% dose).
Chemical Information
-
CAS No. 336784-82-8
-
Appearance Solid
-
Molecular Weight 384.38
-
Formula C21H20O7
-
Color Off-white to light yellow
-
SMILES
COC(C=C1/C=C/C(OCC(/C=C/C2=CC(OC)=C(C=C2)O)=O)=O)=C(C=C1)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (260.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.50 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Research Protocol for Epigenomic Data Analysis
Epigenomic data analysis identifies genome-wide regulatory features that influence gene expression, chromatin state, and phenotype without changing the underlying DNA sequence. In this strategy, the core regulatory layer includes chromatin accessibility, transcription-factor or histone-mark occupancy, DNA methylation, and chromatin-state patterns; these features are measured by sequencing-based assays and interpreted as regulatory elements, promoters, enhancers, repressive domains, methylated cytosines, or candidate phenotype-associated chromatin programs. The literature links epigenomic features to phenotype by showing that functional genomic elements can be mapped across human cell types and tissues, and that integrated epigenomic maps reveal cell-type-specific regulatory programs. ENCODE integrated transcription, chromatin accessibility, transcription-factor occupancy, and histone modification data to annotate functional elements in the human genome, while the Roadmap Epigenomics Co
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Oliveira AL, et al. Calebin A: Analytical Development for Pharmacokinetics Study, Elucidation of Pharmacological Activities and Content Analysis of Natural Health Products. J Pharm Pharm Sci. 2015;18(4):494-514. [Content Brief]
[2]. Brockmueller A, et al. Calebin A modulates inflammatory and autophagy signals for the prevention and treatment of osteoarthritis. Front Immunol. 2024;15:1363947. Published 2024 Mar 4. [Content Brief]
[3]. Brockmueller A, et al. Multifunctionality of Calebin A in inflammation, chronic diseases and cancer. Front Oncol. 2022;12:962066. Published 2022 Sep 16. [Content Brief]
[4]. Lee MJ, et al. Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. Phytomedicine. 2019;57:377-384. [Content Brief]
[5]. Lee PS, et al. Calebin-A prevents HFD-induced obesity in mice by promoting thermogenesis and modulating gut microbiota. J Tradit Complement Med. 2022;13(2):119-127. Published 2022 Jan 5. [Content Brief]
[6]. Buhrmann C, et al. Multitargeting Effects of Calebin A on Malignancy of CRC Cells in Multicellular Tumor Microenvironment. Front Oncol. 2021;11:650603. Published 2021 Sep 29. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6016 mL | 13.0080 mL | 26.0159 mL | 65.0398 mL |
| 5 mM | 0.5203 mL | 2.6016 mL | 5.2032 mL | 13.0080 mL | |
| 10 mM | 0.2602 mL | 1.3008 mL | 2.6016 mL | 6.5040 mL | |
| 15 mM | 0.1734 mL | 0.8672 mL | 1.7344 mL | 4.3360 mL | |
| 20 mM | 0.1301 mL | 0.6504 mL | 1.3008 mL | 3.2520 mL | |
| 25 mM | 0.1041 mL | 0.5203 mL | 1.0406 mL | 2.6016 mL | |
| 30 mM | 0.0867 mL | 0.4336 mL | 0.8672 mL | 2.1680 mL | |
| 40 mM | 0.0650 mL | 0.3252 mL | 0.6504 mL | 1.6260 mL | |
| 50 mM | 0.0520 mL | 0.2602 mL | 0.5203 mL | 1.3008 mL | |
| 60 mM | 0.0434 mL | 0.2168 mL | 0.4336 mL | 1.0840 mL | |
| 80 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.8130 mL | |
| 100 mM | 0.0260 mL | 0.1301 mL | 0.2602 mL | 0.6504 mL |